Caixin
Aug 06, 2022 04:07 AM
BUSINESS

Sanofi Invests $306 Million in China Partnership for Novel Cancer Drugs

The deal will give Sanofi a 3.87% stake in Innovent’s issued shares.
The deal will give Sanofi a 3.87% stake in Innovent’s issued shares.

French pharmaceutical giant Sanofi SA agreed to invest 300 million euros ($306 million) in Chinese biotech company Innovent Biologics Inc. to foster collaboration in cancer drug development.

Under the agreement, Sanofi will buy Innovent’s Hong Kong-traded shares at HK$42.42 ($5.40) each, a 20% premium over the stock’s average price for the past 30 trading days, Innovent Thursday said in a filing.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST
Caixin China Biz Roundup: China Warns Not to Bet Against the Yuan
00:00
00:00/00:00